FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2115201106> ?p ?o ?g. }

• W2115201106 endingPage "458" @default.
• W2115201106 startingPage "450" @default.
• W2115201106 abstract "BackgroundCancer is associated with an increased risk of thromboembolic diseases, but data on the association between prostate cancer and thromboembolic diseases are scarce. We investigated the risk of thromboembolic disease in men with prostate cancer who were receiving endocrine treatment, curative treatment, or surveillance.MethodsWe analysed data from PCBaSe Sweden, a database based on the National Prostate Cancer Register, which covers over 96% of prostate cancer cases in Sweden. Standardised incidence ratios (SIR) of deep-venous thrombosis (DVT), pulmonary embolism, and arterial embolism were calculated by comparing observed and expected (using the total Swedish male population) occurrences of thromboembolic disease, taking into account age, calendar-time, number of thromboembolic diseases, and time since previous thromboembolic disease.FindingsBetween Jan 1, 1997, and Dec 31, 2007, 30 642 men received primary endocrine therapy, 26 432 curative treatment, and 19 526 surveillance. 1881 developed a thromboembolic disease. For men on endocrine therapy, risks for DVT (SIR 2·48, 95% CI 2·25–2·73) and pulmonary embolism (1·95, 1·81–2·15) were increased, although this was not the case for arterial embolism (1·00, 0·82–1·20). Similar patterns were seen for men who received curative treatment (DVT: 1·73, 1·47–2·01; pulmonary embolism: 2·03, 1·79–2·30; arterial embolism: 0·95, 0·69–1·27) and men who were on surveillance (DVT: 1·27, 1·08–1·47; pulmonary embolism: 1·57, 1·38–1·78; arterial embolism: 1·08, 0·87–1·33). Increased risks for thromboembolic disease were maintained when patients were stratified by age and tumour stage.InterpretationAll men with prostate cancer were at higher risk of thromboembolic diseases, with the highest risk for those on endocrine therapy. Our results indicate that prostate cancer itself, prostate cancer treatments, and selection mechanisms all contribute to increased risk of thromboembolic disease. Thromboembolic disease should be a concern when managing patients with prostate cancer.FundingSwedish Research Council, Stockholm Cancer Society, and Cancer Research UK." @default.
• W2115201106 created "2016-06-24" @default.
• W2115201106 creator A5001406891 @default.
• W2115201106 creator A5003951535 @default.
• W2115201106 creator A5010401322 @default.
• W2115201106 creator A5027249096 @default.
• W2115201106 creator A5033731052 @default.
• W2115201106 creator A5045789618 @default.
• W2115201106 creator A5047898396 @default.
• W2115201106 creator A5054505998 @default.
• W2115201106 creator A5076457123 @default.
• W2115201106 date "2010-05-01" @default.
• W2115201106 modified "2023-10-11" @default.
• W2115201106 title "Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden" @default.
• W2115201106 cites W1563927509 @default.
• W2115201106 cites W1964677091 @default.
• W2115201106 cites W1968317122 @default.
• W2115201106 cites W2003375859 @default.
• W2115201106 cites W2004033436 @default.
• W2115201106 cites W2006481491 @default.
• W2115201106 cites W2008549629 @default.
• W2115201106 cites W2009533401 @default.
• W2115201106 cites W2013136992 @default.
• W2115201106 cites W2022211849 @default.
• W2115201106 cites W2026750621 @default.
• W2115201106 cites W2028883041 @default.
• W2115201106 cites W2034934074 @default.
• W2115201106 cites W2054324054 @default.
• W2115201106 cites W2055671944 @default.
• W2115201106 cites W2065084164 @default.
• W2115201106 cites W2071839943 @default.
• W2115201106 cites W2072341098 @default.
• W2115201106 cites W2073244388 @default.
• W2115201106 cites W2082448317 @default.
• W2115201106 cites W2084112863 @default.
• W2115201106 cites W2084350813 @default.
• W2115201106 cites W2105310697 @default.
• W2115201106 cites W2111139930 @default.
• W2115201106 cites W2112636231 @default.
• W2115201106 cites W2114941207 @default.
• W2115201106 cites W2131756199 @default.
• W2115201106 cites W2131778503 @default.
• W2115201106 cites W2147238961 @default.
• W2115201106 cites W2153850083 @default.
• W2115201106 cites W2154753542 @default.
• W2115201106 cites W2157641195 @default.
• W2115201106 cites W2157691983 @default.
• W2115201106 cites W4211024301 @default.
• W2115201106 doi "https://doi.org/10.1016/s1470-2045(10)70038-3" @default.
• W2115201106 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2861771" @default.
• W2115201106 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20395174" @default.
• W2115201106 hasPublicationYear "2010" @default.
• W2115201106 type Work @default.
• W2115201106 sameAs 2115201106 @default.
• W2115201106 citedByCount "109" @default.
• W2115201106 countsByYear W21152011062012 @default.
• W2115201106 countsByYear W21152011062013 @default.
• W2115201106 countsByYear W21152011062014 @default.
• W2115201106 countsByYear W21152011062015 @default.
• W2115201106 countsByYear W21152011062016 @default.
• W2115201106 countsByYear W21152011062017 @default.
• W2115201106 countsByYear W21152011062018 @default.
• W2115201106 countsByYear W21152011062019 @default.
• W2115201106 countsByYear W21152011062020 @default.
• W2115201106 countsByYear W21152011062021 @default.
• W2115201106 countsByYear W21152011062022 @default.
• W2115201106 countsByYear W21152011062023 @default.
• W2115201106 crossrefType "journal-article" @default.
• W2115201106 hasAuthorship W2115201106A5001406891 @default.
• W2115201106 hasAuthorship W2115201106A5003951535 @default.
• W2115201106 hasAuthorship W2115201106A5010401322 @default.
• W2115201106 hasAuthorship W2115201106A5027249096 @default.
• W2115201106 hasAuthorship W2115201106A5033731052 @default.
• W2115201106 hasAuthorship W2115201106A5045789618 @default.
• W2115201106 hasAuthorship W2115201106A5047898396 @default.
• W2115201106 hasAuthorship W2115201106A5054505998 @default.
• W2115201106 hasAuthorship W2115201106A5076457123 @default.
• W2115201106 hasBestOaLocation W21152011061 @default.
• W2115201106 hasConcept C120665830 @default.
• W2115201106 hasConcept C121332964 @default.
• W2115201106 hasConcept C121608353 @default.
• W2115201106 hasConcept C126322002 @default.
• W2115201106 hasConcept C141071460 @default.
• W2115201106 hasConcept C2776265017 @default.
• W2115201106 hasConcept C2777185221 @default.
• W2115201106 hasConcept C2780011451 @default.
• W2115201106 hasConcept C2780192828 @default.
• W2115201106 hasConcept C2780868729 @default.
• W2115201106 hasConcept C2908647359 @default.
• W2115201106 hasConcept C61511704 @default.
• W2115201106 hasConcept C71924100 @default.
• W2115201106 hasConcept C99454951 @default.
• W2115201106 hasConceptScore W2115201106C120665830 @default.
• W2115201106 hasConceptScore W2115201106C121332964 @default.
• W2115201106 hasConceptScore W2115201106C121608353 @default.
• W2115201106 hasConceptScore W2115201106C126322002 @default.
• W2115201106 hasConceptScore W2115201106C141071460 @default.
• W2115201106 hasConceptScore W2115201106C2776265017 @default.

• next